Clinical hold lifted on Cangene's hemophilia FIX
This article was originally published in Scrip
Phase III studies for Cangene's intravenous recombinant Factor IX product IB1001 are to resume after The US FDA lifted the clinical hold previously placed on trials with the compound. Winnipeg-based Cangene acquired the hemophilia B candidate from Ipsen and Inspiration Biopharmaceuticals in February 2013 (scripintelligence.com, 20 February 2013).
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.